Director John W. Frederick filed an initial statement of beneficial ownership with the SEC on November 2, 2026, reporting his holdings in Tempest Therapeutics, Inc. as of the event date of October 13, 2026.

Key Highlights

  • Reporting person: John W. Frederick, identified as a Director of Tempest Therapeutics, Inc.
  • Event date: The date of the event requiring the statement was October 13, 2026.
  • Common stock holdings: Frederick directly owns 8,000 shares of Tempest Therapeutics common stock, according to the filing.
  • No derivative securities: Table II of the filing lists no derivative securities beneficially owned.
  • Late filing noted: The filing states it "is being reported late due to a delay in obtaining EDGAR codes from the Securities and Exchange Commission."
  • Filing date: The form was signed by John Frederick and filed on November 2, 2026.

Director Frederick's Initial Ownership Disclosure at Tempest Therapeutics

John W. Frederick submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - in connection with his role as a Director of Tempest Therapeutics, Inc. (NASDAQ:TPST). The filing covers the period beginning October 13, 2026, which the filing identifies as the date of the event requiring the statement.

According to the filing, Frederick directly holds 8,000 shares of Tempest Therapeutics common stock. The ownership is reported as direct (Form D) with no indirect beneficial ownership reported. Table II, which covers derivative securities such as options, warrants, and convertible securities, contains no entries, indicating that Frederick reported no derivative holdings at the time of filing.

The filing includes a remark explaining the late submission: "This transaction is being reported late due to a delay in obtaining EDGAR codes from the Securities and Exchange Commission." The form was signed as "/s/ John Frederick" and dated November 2, 2026. Frederick's address is listed as c/o Tempest Therapeutics, Inc., 2000 Sierra Point Parkway, Suite 400, Brisbane, California 94005.

What Was Disclosed

A Form 3 initial beneficial ownership statement was filed on November 2, 2026, by Director John W. Frederick of Tempest Therapeutics, Inc., disclosing direct ownership of 8,000 shares of common stock as of October 13, 2026, with no derivative securities reported.